With JN.1 variant spreading, caution and resilience key to smart Covid preparedness
Image used is for representational purposes only
LUCKNOW: India is keeping a close eye on Covid-19 landscape as a modest rise in cases emerges across the country. While the current number of 257 active infections nationwide remains low by historical standards, health experts are urging caution due to regional spikes and the spread of highly transmissible JN.1 variant.
The recent uptick in Kerala, Maharashtra, Tamil Nadu, and Delhi reflect a broader pattern across Southeast Asia, where countries like Singapore, China, Hong Kong, and Thailand are witnessing a fresh surge in cases. The spike is being driven by the JN.1 lineage of Omicron, along with newer offshoots like LF.7 and NB.1.8.
What we know about JN.1
First identified in 2023, JN.1 has steadily gained ground due to its ability to spread.
According to the World Health Organization, it now accounts for over a quarter of all global genomic sequences submitted. Though JN.1 doesn't appear to cause more severe illness, its rapid spread and mutation warrant ongoing surveillance.
The variant carries around 30 mutations that enhance its immune evasion, meaning even previously infected or vaccinated individuals can experience reinfection although most cases remain mild.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Free P2,000 GCash eGift
UnionBank Credit Card
Apply Now
Undo
Symptoms mild, but stay vigilant
Most of the recent Covid-19 cases, especially those linked to the JN.1 variant, are showing up as mild upper respiratory symptoms like sore throat, cough, or a low-grade fever and often settle within a few days. But one must remember that the virus hasn't gone away. People with weaker immunity, the elderly, or those with chronic illness should take precautions. A little care can prevent bigger problems later.
In Mumbai, death of two patients with advanced cancer and kidney disease have sparked renewed concern. While Covid-19 was not deemed the direct cause of death, both patients tested positive and were handled with Covid-appropriate protocols.
What's new on the vaccine front?
In response to the evolving variant landscape, the Centers for Disease Control and Prevention (CDC) has updated its Covid-19 vaccine guidelines for 2024-2025 season.
The latest vaccine formulations are tailored to JN.1 and its descendants.
The CDC recommends one dose of updated vaccine for individuals aged 12–64, and two doses, six months apart, for those aged 65 and above.
The Union health ministry is reviewing data on updated formulations, and discussions are underway regarding rollout strategies should local cases spike further.
India's approach: Prepared, not panicked
Officials from the Union ministry of health and family welfare have reassured citizens that the current situation is under control.
However, they emphasize the importance of maintaining basic preventive measures.
Public health authorities are also encouraging states to ramp up genome sequencing and clinical surveillance through INSACOG, India's genomic consortium.
Why this matters
This moment calls not for panic, but for preparedness. We're in a phase where complete elimination of the virus is unrealistic but what's entirely within our control is how intelligently we respond. Surveillance, timely intervention, and protecting vulnerable people remain the key. Resilience, and not fear, should guide our public health strategy moving forward.
(The writer is a medical scientist and an expert of infectious diseases)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
38 minutes ago
- Time of India
One cough too many: India's TB fight isn't quite there yet
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads MISSING CASES Tired of too many ads? Remove Ads NEW HOPE, OLD GAPS A CURE WITH ISSUES WHAT NEXT? One moment Anushka (name changed) was a college student. Then her world turned upside down. It started with a persistent cough and high fever. Despite popping meds, it wouldn't go away. Tests followed and then came the news that knocked the stuffing out of her—she had a fatal form of tuberculosis TB ). With scarred lungs, she gasped for each breath. The bacteria had killed her appetite, making her frail and bony. Her skin colour changed—to dark and then grew paler. At 20, her life expectancy dwindled to a few months.'I felt weak,' she recalls, 'and preferred to be alone.'Battling extensively drug-resistant tuberculosis or XDR-TB, a form of the disease in which drugs rarely worked, Anushka's only option was to be loaded each day with scores of tablets and injections. Those came with toxic side effects. For over four years, she moved between government and private hospitals, enduring cycles of failed came only when she was placed on a salvage regimen—the last option when all other interventions are exhausted—at a Médecins Sans Frontières (MSF) clinic in Govandi, Mumbai. The global humanitarian group offered Anushka a cocktail of bedaquiline , delamanid and imipenem injections, a set of very powerful meds often inaccessible to most Indians due to supply restrictions aimed at curbing drug who has now recovered, recounted her ordeal at MSF's TB Day event in Mumbai on May 12, speaking before an audience of doctors, a quiet smile breaking through years of pain. Her journey to recovery is rare, and alien to millions in India, which reflects a public health system still failing its most vulnerable. India now accounts for more than a quarter of all TB cases reported worldwide. In 2023, the country had 26% of the global TB burden, according to the World Health Organization (WHO). Bending the curve remains difficult despite multiple national can India improve?In 2018, when India pledged to eliminate TB by 2025, five years ahead of the set global target, the objective was clear. And progress has been made, too. Between 2015 and 2023, TB incidence (new and relapsed cases per 1 lakh population every year) fell by 18% and deaths by 24%, per is a sign in the right direction, but the number of cases are still astounding, especially when it comes to drug-resistant variants. 'India bears the highest burden of XDR-TB globally, with an estimated 110,000 new cases annually,' says Professor Anil Koul of the London School of Hygiene and Tropical Medicine. A key figure in TB drug research, Koul was part of a Johnson & Johnson team that developed bedaquiline, one of the most effective drugs against resistant TB notes that Covid-19 deepened the crisis, and underfunded research has stalled progress. Of the 27 drugs in clinical trials, none have reached Phase III. Bedaquiline remains the mainstay.A 100-day TB Elimination Challenge was launched by the government in December 2024 to amplify efforts to diagnose and treat TB at the village level, but experts aren't satisfied.'We are not on track,' says Dr Animesh Sinha, chronic care and infectious disease advisor, MSF. 'To meet the 2025 milestones of WHO's End TB strategy, India should achieve a 50% reduction in TB incidence rate and a 75% reduction in the total number of TB deaths compared with 2015.' Although numbers have fallen, the quantum has been woefully short of the target, as WHO numbers suggest.A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015.A key problem is underreporting emanating from under-diagnosis. India's notification rate (number of TB cases diagnosed and officially reported) has improved from 108 per 100,000 population in 2010 to 166 in 2023, yet many cases, especially in rural areas, go undetected.'In order to address the TB crisis, we have to find the missing cases,' says Sinha. Nonetheless, the 2025 goal helped push TB up the political agenda. Ni-kshay, a digital platform for notification and treatment monitoring, is improving reporting. But without proportionate investment in diagnostics, staffing and drug access, the pace of progress will be drug shortages have been reported, and India spent just 2.1% of the National Tuberculosis Elimination Programme budget on diagnostics till 2023-24, an IndiaSpend RTI revealed.'The 2025 target was always a stretch,' says Koul. 'But it did galvanise government machinery, leading to faster approvals for newer regimens like bedaquiline, speedier rollout across TB centres and more budgetary support, including for nutritional aid.'That said, TB continues to receive only a sliver of public health funding. But even so, he notes, there certainly is a positive trend in fighting back, considering the complexity of the disease and the socioeconomic factors shaping in an ET Morning Brief podcast in January, Dr Urvashi Singh, deputy director-general (TB), Ministry of Health and Family Welfare, said, 'The domestic budget for the national TB programme has increased over five times in the last 10 years.' India, she added, is the only high-burden country where 91% of the programme is backed by domestic detection is often the difference between quick recovery and years of suffering. Goa-based diagnostic device maker Molbio Diagnostics' Truenat, a portable molecular-testing platform, introduced in 2017, expanded diagnostic access, particularly in low-access regions. 'We supplied over 90 lakh testing kits last year and expect to provide 1.25 crore this year,' says Sriram Natarajan, CEO of Molbio, which is working with government and statelevel partners to rollout molecular testing.A Truenat test costs just Rs 640, a fraction of what imported diagnostics demand, says Natarajan. In public health, he argues, the real measure isn't price, but cost-effectiveness, especially when early detection can avert far greater globally approved diagnostics protocols remain out of reach in India. The WHO-recommended urine TBLAM test, used to diagnose TB in HIVpositive patients, is still unavailable in the country, despite successful validation studies in Mumbai in 2022. Registration barriers and lack of supply from manufacturers have led to lack of access, says Leena Menghaney, a public health lawyer based in Delhi. Supplyrelated issues could be because trials in India have yet to conclude, according to industry delays cost precious lives. Late detection risks high transmission rates and complications for patients. Dr Jennifer Furin, infectious diseases clinician, Harvard Medical School, says while Truenat is helpful and the diagnostic pipeline is robust, the outdated and slow systems for approving novel tools in India have a detrimental impact. Furin points to a critical gap: the lack of household-level prevention. Studies, including a 2023 trial published in TheLancet, show that modest nutritional support for families of TB patients can sharply reduce transmission. Another model, published in TheLancet this year, estimates that improving household nutrition alone could prevent nearly 5% of TB deaths by carrying the world's highest TB burden, regulatory reforms have been slow in India. Some gains have been made, but systemic delays continue to blunt the impact of new patients with drug-resistant TB, a new wave of treatment offers hope, but conditions apply. Regimens like a six-month, all-oral combination termed BPaLM— bedaquiline, pretomanid, linezolid and moxifloxacin—have been game-changers, replacing the gruelling 24-month regimens of daily injections and pills. 'These regimens are better tolerated and highly effective, with about 90% of people completing treatment successfully,' says clinicians welcome the government's push for shorter regimens, access remains limited—only 1,700 patients in India have received them, according to Dr Rupak Singla, head of the department of respiratory medicine, National Institute of Tuberculosis and Respiratory Diseases , Delhi, who spoke at the event in Mumbai. Adoption has lagged due to limited access to drug susceptibility testing for newer drugs, which is crucial for choosing an appropriate treatment BPaLM regimen can't be given in cases where more than one organ system is involved or in patients with severe extrapulmonary disease, 'both of which are common in India,' according to Dr Alpa Dalal, head of unit, Group of TB Hospitals, Sewri, Mumbai. BPaLM should not be prescribed for patients previously treated with bedaquiline, says Dalal, unless drug susceptibility to bedaquiline and linezolid is says even in extensive pulmonary TB, where studies have shown good outcomes with BPaLM, many clinicians are cautious. In longer regimens, patients with extensive lung involvement have had higher relapse rates, compared with patients with limited disease, she explains, and that concern carries over. A study published in OUP's research platform, Oxford Academic, in March 2025 shows that bedaquiline resistance among previously treated patients can reduce the drug's warn that such resistance could undercut its effectiveness in the long term if not addressed early. But Koul says, 'Bedaquiline has galvanised TB R&D. It will remain a core component of future regimens, unless we see a dramatic rise in resistance in clinical practice.'The economics of care create barriers too. Pricing is a big hurdle. Regimens with imipenem cost thousands of rupees per day. Anushka was treated free by MSF. Else each injection alone, she said, would cost Rs 2,499. Considering the socioeconomic realities of India, perhaps this is where the government could step approach to procurement is problematic too. The country selectively joins pooled procurement platforms like the Global Drug Facility, which could reduce costs. 'India has in the past refused to participate in this, unless they had an emergency,' says policy and procurement, TB is a profoundly social disease, shaped by stigma, poverty and undernutrition. Even the best drugs won't work if care doesn't reach those who need it most. Guidelines may improve and approvals may accelerate but until the system meets people where they are, too many will be left suffered for years before she got cured. Her strength wasn't just in surviving; it was in refusing to give up. 'Even in that condition, I completed my graduation and kept chasing my dreams,' she says. India's TB response must now rise to match that grit, with urgency, equity and compassion.
Hindustan Times
40 minutes ago
- Hindustan Times
Ludhiana: 3 new cases take Covid tally to 21
Three new Covid-19 positive cases were reported in the district on Saturday, taking the tally to 21. While two of the new cases, a 38-year-old man and 23-year-old woman, are mildly symptomatic, a 53-year-old man has been hospitalised. According to a senior health official, the patient is only on L2 care which includes oxygen but doesn't include other invasive treatments like those needed in L3 care. The hospitalised man had taken three shots of the vaccine. The mildly symptomatic woman and man had taken three and two shots of vaccine, respectively. Of these 21 cases, only 16 are active. Three of the patients have recovered while two have died so far. Fifteen patients are in home isolation. Both the deaths, one on last Wednesday and the second this Wednesday, were cases of comorbid patients. While the first death was of a 40-year-old suffered from a lung ailment, the second deceased (69-year-old) had been suffered from typhoid for the last five months, and was also obese. Of the 21 cases reported so far in the district, 20 were vaccinated except an 18-year-old.
Time of India
an hour ago
- Time of India
Contraceptive pills linked to heart attack in young woman with PCOS
Mumbai: Unlike many Mumbaikars who disliked April for its sizzling temperatures, Mahim resident, 27-year-old Payal (name changed), has happy memories of the summer month as a new bride. That is, until June 2, when the software engineer spent a day nursing "terrible acidity" that worsened with acute chest pain in the middle of the night and turned out to be a heart attack. "She showed changes in her ECG when she was brought in at 2am that pointed to a heart attack," said cardiologist Dr Kaushal Chhatrapati from Saifee Hospital near Charni Road, who put a stent across her circumflex artery in the early hours of June 3. Payal's heart attack shocked her family because, for one, she is just 27, and for another, women are supposed to have 'protection' against heart disease/attacks during their childbearing years. The protector is the female hormone estrogen, which keeps blood vessels wide enough for blood flow and reduces inflammation. The culprit in Payal's case, according to Dr Chhatrapati, was contraceptive pills she was prescribed for polycystic ovary syndrome (PCOS), a hormonal disorder characterised by irregular periods and the presence of cysts on the ovaries. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like People Born 1940-1975 With No Life Insurance Could Be Eligible For This Reassured Get Quote Undo Payal's father said she struggled for almost a decade with PCOS, and her gynaecologist prescribed the contraceptive pills for seven years. A Denmark study published in 'The BMJ' medical journal in Feb found that the most commonly used hormonal contraceptive—the combined estrogen-progestin pill —was associated with double the risk of ischaemic stroke and heart attack. The article extrapolated this to mean "one extra stroke for every 4,760 women using the combined pill for one year, and one extra heart attack for every 10,000 women per year of use." The study maintained that estrogen-containing products, in particular the vaginal ring and skin patches, were of concern. Gynaecologist Dr Kiran Coelho said strokes are more common than heart attacks due to contraceptive pills. "I have seen 22-year-old and 28-year-old women with PCOS who suffered strokes, but women need the pills to suppress ovulation, which, in turn, reduces the number of cysts in their ovaries," she said. PCOS is often accompanied by obesity and insulin resistance, leading to dyslipidaemia, a condition in which the patient has high levels of lipids (fats) in the blood that can lead to an increased risk of heart disease. "Urban women have high levels of stress, and there is a higher incidence of childhood obesity than before. These factors increase the risk of PCOS in urban India, where one in every five adolescent girls has the hormonal disorder," said Dr Coelho. Cardiologist Dr Rajeev Bhagwat from Nanavati Hospital in Vile Parle said that while it's known that contraceptive pills can increase thrombosis, it's important for doctors to know the woman's family history of heart disease before prescribing these pills. "Family history is a very strong cause for heart disease among the young," he added.
